Prostate Cancer Daily

January 24, 2025

Videos

Peer-to-Peer Clinical Conversations

Combining EZH2 and AR Targeting in Metastatic Castration-Resistant Prostate Cancer - Neeraj Agarwal

Neeraj Agarwal

Zachary Klaassen speaks with Neeraj Agarwal about the Phase III randomized MEVPRO-1 study examining mevrometostat in combination with enzalutamide for mCRPC patients previously treated with abiraterone acetate.

View

Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard

Gerhardt Attard

Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors.

View

Beyond the Abstracts

Pesticides and Prostate Cancer Incidence and Mortality: An Environment-Wide Association Study - Beyond the Abstract

A PSA SNP Associates with Cellular Function and Clinical Outcome in Men with Prostate Cancer - Beyond the Abstract

Conference Coverage

ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer

ASTRO 2024: Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial

ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

SNMMI 2024: Registrational Trials for PSMA PET

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Prostate-specific Membrane Antigen-radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment.

An AI-Digital Pathology Algorithm Predicts Survival after Radical Prostatectomy from the PLCO Trial.

Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.

Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer.

Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate.

Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey.

Update on PSMA-based Prostate Cancer Imaging - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login